ABVC BioPharma, Inc. (ABVC) announced the company, together with its affiliate Rgene Corporation entered into a licensing agreement with OncoX, a private company registered in the British Virgin Islands that specializes in dietary supplements for Oncology. ABVC granted OncoX exclusive rights for one of ABVC's four products in its Oncology pipeline to develop, manufacture, and commercialize BLEX 404, a therapeutic agent for the treatment of NSCLC.'ABVC will spearhead the development of BLEX 404, which has demonstrated promising results in clinical studies,' said Uttam Patil, CEO.ABVC and its affiliate are set to receive an aggregate license fee of $12.5 million in the form of cash or shares of OncoX securities within 30 days of executing the agreement, with an additional milestone payment of $1.25 million in cash after OncoX's next round of fundraising, of which there can be no guarantee; ABVC and its affiliate are also entitled to royalties of 5% of net sales, up to $12.5 million, after the launch of the licensed product..

ABVC BioPharma，Inc.（ABVC）宣布，该公司及其附属公司Rgene Corporation与OncoX签订了许可协议，OncoX是一家在英属维尔京群岛注册的私人公司，专门从事肿瘤学膳食补充剂。ABVC授予OncoX在其肿瘤学管道中的四种产品之一的独家权利，以开发、制造和商业化用于治疗NSCLC的治疗剂BLEX 404。”首席执行官乌塔姆·帕蒂尔（UttamPatil）说，ABVC将率先开发BLEX 404，该产品在临床研究中取得了令人鼓舞的结果。ABVC及其附属公司将在签署协议后30天内以现金或OncoX证券股份的形式收到1250万美元的总许可费，并在OncoX下一轮融资后以125万美元的现金支付额外的里程碑付款，对此无法保证；在许可产品发布后，ABVC及其附属公司也有权获得净销售额的5%的版税，最高可达1250万美元。。

For More Such Health News, visit rttnews.com. For comments and feedback contact: editorial@rttnews.comBusiness News

有关更多此类健康新闻，请访问rttnews.com。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股